Webinar Series of the Chinese Antibody Society
We don't have any active meetings as of now. New meetings will show up here as registration opens. Check back soon!
Sign in to view recordings
12/07/2024
Dr. Antonios (Tony) Aliprantis
Antibody treatments have been available for over 2 decades for non-oncology indications, particularly in immunology. In this presentation, Dr. Aliprantis will use case studies from his clinical practice and drug development experience to highlight the antibody characteristics that are most important to patients and how these drugs can be delivered …
10/26/2024
Dr. Sandra Gabelli
突变相关肿瘤新抗原(MANAs)在癌症免疫治疗中被视为极具潜力的靶点，因为它们只在肿瘤细胞中表达，避免了对正常组织的损伤。这一独特特性为开发靶向MANAs的抗体药物开辟了新的治疗路径。抗体疗法的精准性为难治性肿瘤提供了新的希望。近年来，冷冻电子显微镜（CryoEM）技术的发展，进一步推动了抗体设计的进步。CryoEM能够以近原子分辨率揭示抗体与MANAs的相互作用，帮助科学家深入理解抗体结合位点及其机制，为抗体优化提供了关键的结构性见解。 通过这种方式，研究人员能够开发出更高效且特异性更强的抗体药物。这不仅可以显著提升抗癌疗效，还能够减少副作用，进而提高患者的生活质量。随着CryoEM技术的进步，抗体药物开发的速度和精度有望进一步提升，使靶向突变相关新抗原的治疗策略成为精准癌症治疗中的重要组成部分。
09/28/2024
Dowdy Jackson
Antibody drug conjugates (ADCs) are rapidly becoming the standard of care for cancer treatment. This has led to a resurgence of investment in the development of ADCs. ADC focused merger/acquisitions and partnership totaled almost $100 billion USD in 2023. This is more than three times the value of similar ADC …
08/24/2024
Dr. Cheng Liu
Solid tumors represent approximately 90% of all cancers. Chimeric antigen receptor T (CAR-T) cells have shown promising outcomes in the treatment of hematologic malignancies. However, CAR-T cell therapy in solid tumor treatment has been significantly hindered, due to the complex tumor microenvironment (TME) in solid tumors affects the proliferation and …